Patents by Inventor Hiroki Torikai

Hiroki Torikai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS
    Publication number: 20240156929
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Application
    Filed: September 12, 2023
    Publication date: May 16, 2024
    Inventors: Laurence J.N. COOPER, Hiroki TORIKAI, Ling ZHANG, Helen HULS, Feng WANG-JOHANNING, Lenka HURTON, Simon OLIVARES, Janani KRISHNAMURTHY
  • Human application of engineered chimeric antigen receptor (CAR) T-cells
    Patent number: 11786582
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: October 17, 2023
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laurence J N Cooper, Hiroki Torikai, Ling Zhang, Helen Huls, Feng Wang-Johanning, Lenka Hurton, Simon Olivares, Janani Krishnamurthy
  • METHODS FOR RAPID CLONING AND EXPRESSION OF HLA CLASS I CELLS
    Publication number: 20230079539
    Abstract: The present disclosure provides methods of generating HLA class-I null cells that can be used for expression of exogenous HLA genes and presentation of antigens, such tumor neoantigens. Method for using HLA class-I null cells from selecting, stimulating and propagating immune effector cells are also provided.
    Type: Application
    Filed: February 10, 2021
    Publication date: March 16, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Hiroki TORIKAI, Shan ZONG
  • METHODS AND COMPOSITIONS FOR MODIFICATION OF HLA
    Publication number: 20220202858
    Abstract: Disclosed herein are methods and compositions for modulating the expression of a HLA locus, including Natural Killer (NK) cells that lack expression of one or more classic HLA genes and comprise one or more exogenous sequences that express one or more non-classic HLA gene.
    Type: Application
    Filed: July 22, 2021
    Publication date: June 30, 2022
    Inventors: Philip D. Gregory, Laurence J.N. Cooper, Hiroki Torikai
  • Car+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
    Patent number: 11344577
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising disrupted T cell receptor and/or HLA and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf” treatment of medical conditions such as cancer, autoimmunity, and infection. In particular embodiments, the T cell receptor-negative and/or HLA-negative T cells are generated using zinc finger nucleases, for example.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: May 31, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laurence J. Neil Cooper, Hiroki Torikai
  • HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS
    Publication number: 20220062396
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Application
    Filed: April 6, 2021
    Publication date: March 3, 2022
    Inventors: Laurence JN COOPER, Hiroki TORIKAI, Ling ZHANG, Helen HULS, Feng WANG-JOHANNING, Lenka HURTON, Simon OLIVARES, Janani KRISHNAMURTHY
  • HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS
    Publication number: 20200085929
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Application
    Filed: August 19, 2019
    Publication date: March 19, 2020
    Inventors: Laurence JN COOPER, Hiroki TORIKAI, Ling ZHANG, Helen HULS, Feng WANG-JOHANNING, Lenka HURTON, Simon OLIVARES, Janani KRISHNAMURTHY
  • CAR+ T CELLS GENETICALLY MODIFIED TO ELIMINATE EXPRESSION OF T-CELL RECEPTOR AND/OR HLA
    Publication number: 20190388472
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising disrupted T cell receptor and/or HLA and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf” treatment of medical conditions such as cancer, autoimmunity, and infection. In particular embodiments, the T cell receptor-negative and/or HLA-negative T cells are generated using zinc finger nucleases, for example.
    Type: Application
    Filed: July 8, 2019
    Publication date: December 26, 2019
    Inventors: Laurence J. Neil COOPER, Hiroki TORIKAI
  • CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
    Patent number: 10391126
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising disrupted T cell receptor and/or HLA and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf treatment of medical conditions such as cancer, autoimmunity, and infection. In particular embodiments, the T cell receptor-negative and/or HLA-negative T cells are generated using zinc finger nucleases, for example.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: August 27, 2019
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laurence J. Neil Cooper, Hiroki Torikai
  • HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS
    Publication number: 20170224798
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Application
    Filed: February 16, 2017
    Publication date: August 10, 2017
    Inventors: Laurence JN COOPER, Hiroki TORIKAI, Ling ZHANG, Helen HULS, Feng WANG-JOHANNING, Lenka HURTON, Simon OLIVARES, Janani KRISHNAMURTHY
  • METHODS AND COMPOSITIONS FOR MODIFICATION OF HLA
    Publication number: 20170216358
    Abstract: Disclosed herein are methods and compositions for modulating the expression of a HLA locus, including cells that lack expression of one or more classic HLA genes but are not targeted by Natural Killer (NK) cells for lysis.
    Type: Application
    Filed: April 18, 2017
    Publication date: August 3, 2017
    Inventors: Philip D. Gregory, Laurence J.N. Cooper, Hiroki Torikai
  • Human application of engineered chimeric antigen receptor (CAR) T-cells
    Patent number: 9629877
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: April 25, 2017
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laurence JN Cooper, Hiroki Torikai, Ling Zhang, Helen Huls, Feng Wang-Johanning, Lenka Hurton, Simon Olivares, Janani Krishnamurthy
  • APPLICATION OF INDUCED PLURIPOTENT STEM CELLS TO GENERATE ADOPTIVE CELL THERAPY PRODUCTS
    Publication number: 20170044500
    Abstract: The application of induced pluripotent stem cells (iPSCs) to generate adoptive cell therapy products and usage of iPSCs for screening potential toxicity of immune receptors are described herein. In some aspects, iPSCs and cells differentiated therefrom are provide which do not express a HLA gene (e.g., HLA-A).
    Type: Application
    Filed: April 24, 2015
    Publication date: February 16, 2017
    Inventors: Laurence JN COOPER, Hiroki TORIKAI
  • HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS
    Publication number: 20160158285
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Application
    Filed: May 14, 2014
    Publication date: June 9, 2016
    Inventors: Laurence JN COOPER, Hiroki TORIKAI, Ling ZHANG, Helen HULS, Feng WANG-JOHANNING, Lenka HURTON, Simon OLIVARES, Janani KRISHNAMURTHY
  • METHODS AND COMPOSITIONS FOR MODIFICATION OF HLA
    Publication number: 20150037304
    Abstract: Disclosed herein are methods and compositions for modulating the expression of a HLA locus, including cells that lack expression of one or more classic HLA genes but are not targeted by Natural Killer (NK) cells for lysis.
    Type: Application
    Filed: March 12, 2014
    Publication date: February 5, 2015
    Inventors: Philip D. Gregory, Laurence J.N. Cooper, Hiroki Torikai
  • CAR+ T CELLS GENETICALLY MODIFIED TO ELIMINATE EXPRESSION OF T-CELL RECEPTOR AND/OR HLA
    Publication number: 20140349402
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising disrupted T cell receptor and/or HLA and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf treatment of medical conditions such as cancer, autoimmunity, and infection. In particular embodiments, the T cell receptor-negative and/or HLA-negative T cells are generated using zinc finger nucleases, for example.
    Type: Application
    Filed: November 16, 2012
    Publication date: November 27, 2014
    Applicant: Board of Regents, The University of Texas System
    Inventors: Laurence J. Neil Cooper, Hiroki Torikai